FDA accepts NDA filing by Biogen and Sage for zuranolone
After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of 5 August 2023. The drug is being evaluated
Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.
AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use along with monoclonal antibodies or innate-cell engagers in the out-patient environment. Artiva